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ABSTRACT
Background The human tumor microenvironment 
(TME) is a complex and dynamic milieu of diverse 
acellular and cellular components, creating an 
immunosuppressive environment, which contributes 
to tumor progression. We have previously shown that 
phosphatidylserine (PS) expressed on the surface of 
exosomes isolated from human TMEs is causally linked 
to T- cell immunosuppression, representing a potential 
immunotherapeutic target. In this study, we investigated 
the effect of ExoBlock, a novel PS- binding molecule, on 
T- cell responses in the TME.
Methods We designed and synthesized a new compound, 
(ZnDPA)
6- DP- 15K, a multivalent PS binder named ExoBlock. 
The PS- binding avidity of ExoBlock was tested using an in 
vitro competition assay. The ability of this molecule to reverse 
exosome- mediated immunosuppression in vitro was tested 
using human T- cell activation assays. The in vivo therapeutic 
efficacy of ExoBlock was then tested in two different human 
tumor xenograft models, the melanoma- based xenomimetic 
(X- )mouse model, and the ovarian tumor- based omental tumor 
xenograft (OTX) model.
Results ExoBlock was able to bind PS with high avidity 
and was found to consistently and significantly block the 
immunosuppressive activity of human ovarian tumor and 
melanoma- associated exosomes in vitro. ExoBlock was also 
able to significantly enhance T cell- mediated tumor suppression 
in vivo in both the X- mouse and the OTX model. In the X- 
mouse model, ExoBlock suppressed tumor recurrence in a T 
cell- dependent manner. In the OTX model, ExoBlock treatment 
resulted in an increase in the number as well as function of 
CD4 and CD8 T cells in the TME, which was associated with 
a reduction in tumor burden and metastasis, as well as in the 
number of circulating PS+ exosomes in tumor- bearing mice.
Conclusion Our results establish that targeting exosomal 
PS in TMEs with ExoBlock represents a promising strategy 
to enhance antitumor T- cell responses.
INTRODUCTION
Conventional cancer treatment strategies such 
as surgery, radiotherapy and chemotherapy 
often lead to tumor recurrence and metas-
tasis. The use of immunotherapy to eradicate 
tumor and eliminate tumor metastasis by 
inducing antitumor immunological responses 
has met with resounding success, revolution-
izing oncology in the last decade. Targeting 
immune checkpoints using monoclonal anti-
bodies, termed checkpoint blockade therapy, 
has shown promise against multiple cancers. 
However, the response rate among patients 
is highly variable, leaving room for improve-
ment.1 Identification of novel therapeutic 
targets and designing stand- alone or combi-
nation targeting strategies can potentially 
improve outcomes and patient survival.
Phosphatidylserine (PS) is a phospholipid 
that is normally present on the inner leaflet 
of normal cells. However, apoptotic as well as 
non- apoptotic cancer cells such as malignant 
melanoma, leukemia, neuroblastoma, and 
gastric carcinoma have been shown to widely 
express PS on their surfaces.2 PS exposed 
on the surface of tumor cells contributes to 
suppression of T- cell activity and blocks tumor 
clearance.3 4 PS blockade in a mouse model 
of melanoma has been shown to significantly 
reduce tumor size and tumor necrosis area.5
Multiple studies have documented the 
presence of immunosuppressive nanosized 
extracellular vesicles (EVs), called exosomes, 
in the microenvironment of many different 
types of human tumors.6–15 These reports 
have strongly suggested that these exosomes 
contribute to the arrest of antitumor T- cell 
responses. We and others have predicted that 
blockade of immunosuppressive exosomes 
would enhance the strength and durability 
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PD- L1 + exosomes released from melanomas in patients 
have been shown to suppress the function of CD8 T cells 
and to facilitate tumor growth, while the elimination of 
tumor- derived exosomes suppresses tumor growth and 
increases survival in mice.16 17 Multiple studies have estab-
lished a causal link between exosome- mediated immune 
suppression and PS on the surface of exosomes.6–8 Based 
on these studies, we predicted that PS represents a poten-
tial therapeutic target. Molecules that bind with high 
avidity to PS on tumor cells, other apoptotic cells, and 
exosomes could potentially block PS- mediated immune 
suppression.
We have designed and synthesized a new molecule, 
(ZnDPA)6- DP- 15K, that binds PS with high avidity. We 
report here that this molecule, which we have named 
ExoBlock, consistently and effectively blocks immuno-
suppressive exosomes. We first demonstrate that ExoB-
lock has the ability to significantly reverse T- cell immune 
suppression mediated by exosomes derived from human 
ovarian and melanoma tumor tissues in vitro. The in vivo 
therapeutic efficacy of ExoBlock was then tested using 
two tumor xenograft models: (1) the melanoma- based 
xenomimetic (X- )mouse model that was developed and 
validated to evaluate the therapeutic efficacy of strategies 
that are designed to enhance T- cell antitumor responses 
using patient- derived T cells and patient- derived neoan-
tigen expressing tumor target cells18; and (2) the ovarian 
tumor- based omental tumor xenograft (OTX) model 
that represents a more complete microenvironment, 
established using ovarian tumor aggregates derived from 
patients.19 Using these models, we establish here that 
treatment of tumor xenograft- bearing mice with ExoB-
lock results in a significant suppression of tumor growth 
and dissemination, with concomitant enhancement of 
antiumor T- cell responses. We conclude that targeting 
PS using ExoBlock represents a viable strategy to target 
immunosuppressive exosomes and thereby enhances 





Ascites fluids and solid tumors from patients with stage III 
or stage IV ovarian canccers were received anonymously 
under an approved institutional review board protocol 
from the Roswell Park Comprehensive Cancer Center 
(RPCCC) Tissue Procurement Facility. All the tumors 
obtained were high- grade serous epithelial ovarian carci-
nomas. Experiments were done using cell- free ascites 
fluids that had been stored at −80°C. Normal donor 
peripheral blood was provided by the Flow and Image 
Cytometry Facility at RPCCC. Normal donor peripheral 
blood lymphocytes (NDPBL) were obtained by mono-
cyte depletion and Ficoll–Hypaque density separation. 
Cells were cryopreserved in liquid nitrogen until use. 
Specimens from 12 different patients with ovarian cancer 
and NDPBL from 10 different donors were used in this 
study.
Cell culture
DM6- Mut cells and TKT R438W cells were generated and 
authenticated as described previously.18 20 DM6- Mut cells 
and Jurkat cells were maintained in RPMI- 1640 supple-
mented with 10% heat- inactivated fetal bovine serum 
(FBS), 2 mM L- glutamine, 20 U/mL penicillin, 20 µg of 
streptomycin, and 50 µM 2- mercaptoethanol (complete 
medium) at 37°C under 5% CO2. DM6- Mut cells are 
adherent and were grown in 75 or 175 cm3 flasks until 
they were 90% confluent. Cells were harvested with 0.25% 
trypsin- EDTA for 3–4 min at 37°C following removal of 
the medium and washed with phosphate- buffered saline 
(PBS). Complete medium was added to stop the reaction, 
and cells were centrifuged at 300×g for 10 min.
Mice
NOD.Cg- Prkdcscid Il2rgtm1Wjl (NSG) mice (young adult 
female mice), raised in a research colony at The Jackson 
Laboratory, were used in this study as they have been 
shown to support the growth of a variety of human 
tumors.18 19 21 Age- matched and sex- matched mice were 
randomly assigned to control (untreated) and test 
(ExoBlock- treated) groups.
ExoBlock
ExoBlock was synthesized at Molecular Targeting Tech-
nologies Inc. (MTTI) at the 0.5 g scale. Structural integ-
rity and consistency between different batches was 
confirmed using nuclear magnetic resonance studies as 
well as amino group analysis.
In vitro competition study
Apoptosis was induced in Jurkat cells by culture 
(16–20 hours) with 10 µM etoposide (Sigma Aldrich) 
at 1×106/mL. Cells were then washed, resuspended in 
N- tris- (hydroxymethyl)- methyl- 2- aminoethane sulfonic 
acid (TES) buffer (5 mM TES, 145 mM NaCl, pH=7.4). 
The cells were then stained with PSVue 499 (MTTI, Cat# 
P- 1009) at 10 µM in the presence or absence of equim-
olar or titrating amounts of ExoBlock using the protocol 
provided by the manufacturer. Sytox Red (Life Technol-
ogies) was used to exclude dead cells. The samples were 
acquired using an LSRFortessa (BD Biosciences) flow 
cytometer and data analyzed using FlowJo (Tree Star).
In vitro efficacy studies
Tumor- associated exosomes were isolated by ultracentrif-
ugation as described previously7 8 (online supplemental 
methods). T cells from NDPBL were stimulated using 
immobilized antibodies to CD3 and CD28, and activation 
was monitored using the nuclear translocation of NFκB, 
upregulation of the activation markers CD25 and CD69, 
intracellular expression of the cytokines IFN-γ and IL- 2, 
or proliferation as described previously7 8 (online supple-
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exosomes were preincubated with 10 µM ExoBlock for 
1 hour at 37°C.
Isolation of exosomes from mouse sera
Serum was collected from the mice and stored at −80°C. 
Exosomes were isolated by size column exclusion using 
a qEVsingle/35+ nm column (Izon Science, Cat# qEVs-
ingle/35 nm) that isolated particles in the range of 
35–350 nm according to manufacturers’ instructions. 
Briefly, 250 µL of serum was loaded on to a qEVsingle/35+ 
nm column and chased with sterile 1× PBS. Elution frac-
tions of 200 µL were collected and analyzed for particle 
size and concentration by NTA and protein concentra-
tion by Bicinchoninic Acid (BCA) protein assay (Thermo 
Fisher Scientific, Cat# 23227), respectively. Based on 
these parameters, the three elution fractions containing 
the highest concentration of particles and protein levels 
below 500 µg/mL were combined to an enriched exosome 
fraction, and small aliquots were frozen at −80°C until 
further analysis.
Exoglow-NTA and PSVue staining of exosomes
Exosomes were stained with PSVue- 480 (Molecular 
Targeting Technologies, Cat # P- 1003) and ExoGlow- NTA 
(System Biosciences, Cat# EXONTA110A- 1) according to 
manufacturers’ instructions. PSVue binds PS and ExoGlow 
stains vesicles with intact membranes but not membrane 
fragments and non- membrane- associated (lipo)- protein 
aggregates. Briefly, exosomes or an equivalent volume of 
PSVue staining buffer only control (without exosomes) 
were stained first with PSVue followed by staining with 
ExoGlow. Following staining, each sample was divided in 
two 50 µL aliquots. One was diluted 1:5 in PSVue staining 
buffer for acquisition on the ImageStream. The second 
aliquot received an equal volume of 10% Triton- X100, and 
this was diluted 1:5 in PSVue staining buffer for acquisition 
acquired on the ImageStream (see online supplemental 
methods). The Triton- X100- treated samples served as a 
control to determine the concentration of non- exosome 
particles insensitive to detergent lysis (eg, protein aggre-
gates or stain aggregates present in the preparations of 
exosomes and/or the staining reagents.
In vivo studies
The sample size for in vivo experiments was calculated 
based on the ability to demonstrate with 85% power, a 
twofold difference in tumor burden, allowing for a 30% 
SD in tumor size and spread assuming a normal distri-
bution of the samples. The X- mouse model18 and the 
OTX model19 were established as described previously 
(see online supplemental methods). For the X- mouse 
model, the tumor- bearing mice were treated with ExoB-
lock (32 mg/kg) or nivolumab (10 mg/kg) at various time 
points as described, and tumor burdens were estimated as 
described previously18 (online supplemental methods). 
For the OTX model, tumor- bearing mice were treated 
with 107 mg/kg of ExoBlock at various time points as 
described. This dose (107 mg/kg) was also used in the 
toxicity studies. Untreated tumor- bearing mice served as 
controls. Five animals were housed per cage, and exper-
iments were terminated on the noted time points based 
on initial tumor growth kinetics studies, or earlier if signs 
of duress were observed.22
Analysis of changes in gene expression in the OTX model
On day 25, the mice were euthanized; greater omentum 
was harvested and snap- frozen for cryopreservation. 
The cryopreserved samples were thawed; 1 mL of Trizol 
(Life Technologies) was added; and the tumor- bearing 
omental tissue was mechanically disrupted using a SCIL-
OGEX D- 160 homogenizer. RNA isolation was done as 
per the manufacturer’s instructions. RNA of 1 µg was used 
for cDNA synthesis using the iScript cDNA synthesis kit 
(BioRad) as described by the manufacturer. cDNA of 100 
ng was used to set up real- time PCR in a volume of 20 µL 
to determine the expression of human EpCAM, CD4, 
CD8, IFN-γ and Foxp3 using the iQ SYBR Green Supermix 
(BioRad) according to the manufacturer’s instructions 
using a CFX96 Connect Real Time PCR Detection System 
(BioRad). The primers used are listed in online supple-
mental table 1. The thermal cycling conditions included 
an initial denaturation step at 95°C for 10 min, followed 
by 40 cycles at 95°C for 30 s, 58°C for 30 s, and plate read. 
Melting curve analysis of every qPCR was conducted after 
each cycle, and samples with cycle numbers more than 35 
were excluded. Relative gene expression was determined 
by 2−ΔΔCT method by normalizing to (human) β-actin for 
the respective sample.
Statistics
All statistics were calculated using Excel V.2016 (Micro-
soft) and Prism (Graph Pad). Paired or unpaired 
Student’s t- test was applied to determine whether the 
differences between groups could be considered signif-
icant. A p value higher than 0.05 was not significant, 
whereas *p<0.05, **p<0.01, and ***p<0.001 were consid-
ered significant.
RESULTS
Design and synthesis of ExoBlock, a novel drug that binds to 
PS with high avidity
The role of PS in immunosuppression6 23 makes it 
an attractive immunotherapeutic target. Based on 
nanoparticle tracking analysis (NTA) data, we have 
estimated that ovarian ascites fluids contain over 
1×1010 PS+ exosomes per millilitre. Synthetic zinc(ii)- 
dipicolylamine (ZnDPA) co- ordination complexes 
that mimic annexin V, such as the commercially avail-
able PSVue, have been used to bind and visualize PS 
in different environments including cardiovascular 
diseases, bacterial infections, and cancers.24 Some of the 
advantages of these molecules over annexin V include 
greater stability, faster binding kinetics, and intense 
labeling due to smaller size. ZnDPA complexes are 
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other phospholipids.25 We have synthesized a new mole-
cule, a multimerized version of ZnDPA named ExoB-
lock ((ZnDPA)6- DP- 15K) (patent pending). ExoBlock 
(figure 1A) was synthesized at the 0.5 g scale via eight 
synthetic steps with an overall synthetic yield of ~18% 
(online supplemental figure S1). The final product 
was purified by a dialysis process and then eventually 
lyophilized to produce ExoBlock.
With multiple PS binding sites, the hexamer ExoBlock 
is expected to bind with high avidity to PS. To deter-
mine the relative avidity of ExoBlock for PS binding, 
apoptosis was induced in Jurkat cells, and equimolar or 
titrating amounts of ExoBlock were coincubated with 
10 µM PSVue 499, a commercially available ZnDPA- based 
PS- binding probe. We found that not only ExoBlock was 
able to outcompete PSVue at equimolar amounts, but also 
even amounts as low as 1/30 molar equivalents blocked 
more than 50% of PSVue binding, confirming its superior 
avidity for PS (figure 1B–D).
We also performed a preliminary systemic organ 
toxicity study in mice with ExoBlock. NSG mice were 
treated with ExoBlock and euthanized 15 days after 
treatment. Selected organs from treated and control 
untreated mice were removed, fixed, sectioned, stained, 
and examined for the evidence for histopathology. No 
pathological changes were observed at the gross or 
microscopic level in the lung, spleen, small intestine, 
kidney, or liver. We conclude that ExoBlock has no 
observable adverse effects at this dose and schedule in 
NSG mice.
Human ovarian TMEs are enriched in PS-expressing exosomes
We have previously established that the immunosup-
pressive activity of exosomes is causally linked with PS 
expressed on exosomal surfaces. To determine exosomal 
PS expression, exosomes derived from ovarian tumor 
ascites fluids were attached to latex beads, and PS was 
detected using an anti- PS antibody using flow exometry. 
We observed the abundant expression of PS on these 
exosomes (figure 2A). To determine whether TMEs 
are enriched in PS+ exosomes, we quantified ExoG-
low+PSVue+ exosomes in plasma from normal donors 
as well as in ascites fluids from patients with ovarian 
cancer using imaging flow cytometry (IFC). IFC allows 
for the detection of fluorescence intensities on indi-
vidual exosomes as opposed to the flow exometry, which 
determines the fluorescence intensities of heterogeneous 
exosome populations immobilized on capture beads. 
Hence, IFC can visualize heterogeneous expression of 
PS on exosomes, whereas flow exometry cannot. Ovarian 
TMEs were found to be highly enriched in PS+ exosomes, 
and PS+ exosomes comprised more than 90% of the total 
exosomes in 9 out of 10 ascites fluids tested (figure 2B,C). 
On the contrary, the proportions of PS+ exosomes were 
variable but significantly lower in normal donor plasma 
(figure 2B,C).
ExoBlock rescues T cells from immunosuppression mediated 
by exosomes isolated from human ovarian TMEs in vitro
We have previously demonstrated that exosomes isolated 
from human ovarian tumor ascites fluids arrest CD4 + 
Figure 1 ExoBlock competitively inhibits binding of PSVue 499 to apoptotic cells in a dose- dependent manner. (A) Structure 
of ExoBlock. (B–D) Jurkat cells were treated with 10 µM etoposide for 20 hours to induce apoptosis. The cells were then stained 
with PSVue with equimolar or titrating molar amounts of ExoBlock. Sytox red was used to eliminate dead cells from the analysis. 
The experiment was done in triplicate wells. (B) Representative data and (C) quantified data from three wells for equimolar 
amounts of ExoBlock. (D) Dose dependency of the competitive inhibition highlighting the inverse relationship between ExoBlock 
dose and detection of PSVue fluorescence. The amount of fluorescence in resting cells is shown as baseline (21.3±5.7) (D). Data 
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and CD8+ T- cell signaling through the TCR.6 This 
signaling arrest is reflected in multiple T- cell activation 
endpoints, including the nuclear translocation of nuclear 
factor kappa B (NFκB), upregulation of the activation 
marker CD69, intracellular expression of the cytokines 
interferon gamma (IFN-γ) and interleukin (IL)- 2, and 
proliferation.6–8 This inhibitory effect could be signifi-
cantly reversed by blocking PS using PS- binding molecules 
such as annexin V or anti- PS antibodies.6 Since ExoB-
lock has high avidity for PS due to its multivalency, we 
tested the ability of ExoBlock to reverse the immunosup-
pressive effect of exosomes derived from ovarian tumor 
ascites fluids on T- cell function after short- term as well 
as long- term activation through the TCR. As expected, 
T- cell activation was significantly inhibited by exosomes 
regardless of the endpoint, and ExoBlock treatment was 
able to reverse this effect (figure 3A–J and table 1). This 
included nuclear translocation of NFκB (figure 3A,B), 
upregulation of activation markers CD69 (figure 3C,D) 
and CD25 (figure 3E,F), intracellular expression of the 
cytokines IL- 2 (online supplemental figure S2) and IFN-γ 
(figure 3G,H), and proliferation (figure 3I,J and online 
supplemental figure S3). Moreover, a comparison of the in 
vitro efficacies of different PS- binding molecules revealed 
that ExoBlock was significantly better than annexin V and 
was comparable to anti- PS antibody in terms of reversing 
exosome- mediated inhibition (figure 3B). These results 
establish that blockade of PS with ExoBlock can rescue T 
cells from exosome- mediated signaling arrest.
ExoBlock rescues T cells from immunosuppression 
mediated by exosomes isolated from human melanoma 
microenvironments in vitro
To extend these findings to other human TMEs, we 
chose DM6- Mut cells—a human melanoma cell line 
that expresses (melanoma) patient- derived neoantigen 
peptides. The parent cell line, DM6, is an established 
melanoma model for immunotherapy with high clinical 
relevance. Xenografts were established in the greater 
omentum of globally immunodeficient NSG mice by 
the intraperitoneal injection of DM6- Mut cells. If left 
untreated, the tumors progress rapidly and metastasize, 
and the animals develop ascites fluid in 20–25 days.18 To 
demonstrate the presence of exosomes in these microen-
vironments, we isolated and characterized EVs derived 
from DM6- Mut tumor xenografts. NTA, a technique 
commonly employed to determine the size of these 
vesicles, revealed that the DM6- Mut EVs had a modal 
Figure 2 TMEs are enriched in PS. (A) PS expression in ovarian tumor ascites fluid- derived exosomes was determined 
using latex bead flow exometry. Unstained (filled gray histogram), secondary antibody control (open red histogram) and PS- 
stained exosomes (filled blue histogram). (B,C) The percentage of PS+ vesicles in normal donor plasma as well as in patient- 
derived ovarian tumor ascites fluids (TME) was determined using imaging flow cytometry. (B) Compiled data (n=10) and (C) 
representative data for each cohort are shown. Data shown as mean±SEM. Whiskers and outliers were calculated using the 
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Figure 3 ExoBlock reverses immunosuppression mediated by ovarian tumor- associated exosomes in vitro. (A–D) T cells were 
either left unactivated (Unact), activated for 2 hour with immobilized antibodies to CD3 and CD28 without exosomes (Act), with 
exosomes only (Act  + Exo), or with exosomes and ExoBlock (Act  + Exo + ExoBlock). Activation was monitored by detecting 
the nuclear translocation of NFκB using confocal microscopy (A,B) or by detecting the upregulation of CD69 on CD3 + T 
cells using flow cytometry following overnight incubation (representative data shown in C, quantified data shown in D). (B) A 
comparison of the in vitro efficacies of different PS- binding molecules in terms of reversing inhibition of NFκB translocation. (E–
H) T cells were either left Unact, activated for 72hours with immobilized antibodies to CD3 and CD28 without exosomes (Act), 
Act  + Exo, or Act  + Exo + ExoBlock. Activation was monitored by detecting the upregulation of CD25 (representative data 
shown in E, quantified data shown in F) or the expression of intracellular IFN-γ (representative data shown in G, quantified data 
shown in H). (I–J) T cells labeled with CellTrace violet were either left Unact, activated for 7 days with immobilized antibodies 
to CD3 and CD28 without exosomes (Act), Act  + Exo, or Act  + Exo + ExoBlock. Proliferation was assessed by monitoring 
dye dilution using flow cytometry. (I) Representative dye dilution profiles and (J) expansion indices (depicting fold expansion 
of the culture) are shown. n=3. Data shown as mean±SEM. *P≤0.05, **P≤0.01, ***P≤0.001. Act + Exo, Act with exosomes only; 
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diameter of 100 nm (online supplemental figure S4A). 
The presence of exosomal markers was then tested using a 
commercially available antibody platform called exosome 
antibody array. We found that these vesicles expressed 
abundant CD81 and EpCAM, while TSG101, FLOT1, 
ICAM, annexin V, and ALIX were also detected (online 
supplemental figure S4B), establishing the identity of 
these EVs as exosomes. The absence of GM130 indi-
cated that our exosome preparations were not contam-
inated with cellular debris (online supplemental figure 
S4B). Exosomal PS expression was detected using latex 
bead flow exometry as described previously. We found 
that these exosomes expressed high levels of PS on their 
surface (figure 4A).
Table 1 ExoBlock reverses exosome- mediated inhibition of different T- cell activation endpoints
Activation period Activation endpoint
% inhibition with 
exosomes
% inhibition with 
exosomes+ExoBlock
% reversal of 
Inhibition by 
ExoBlock
2 hours Nuclear translocation of NFκB 53 15 71
2 hours CD69 upregulation 46 11 75
6 hours Intracellular IL- 2 expression 45 11 75
3 days Intracellular IFN-γ expression 69 26 63
3 days CD25 upregulation 77 13.5 82
7 days Proliferation (Expansion Index) 67 15.5 77
IFN-γ, interferon gamma; IL, interleukin.
Figure 4 ExoBlock reverses immunosuppression mediated by melanoma- associated exosomes in vitro and suppresses 
melanoma tumor escape in the X- mouse model. (A) PS expression in melanoma- derived exosomes was determined using 
latex bead flow exometry. Unstained (filled gray histogram), secondary antibody control (open red histogram) and PS- stained 
exosomes (filled blue histogram). (B,C) T cells were either left Unact, activated for 2 hours with immobilized antibodies to CD3 
and CD28 without exosomes (Act), Act +Exo, or Act +Exo+ExoBlock. Activation was monitored by detecting the upregulation 
of CD69 on CD3 + T cells using flow cytometry following overnight incubation. (B) Representative data and (C) quantified data 
from three independent experiments are shown. (D) Experimental scheme indicating the timeline for injection of tumor cells 
(green arrow), TKT R438W cells (blue arrow), treatment with anti- PD1 or ExoBlock (brown arrows) and estimation of tumor 
burden (red arrows). (E) Representative images of omental tumor burdens on day 25. (F) Tumor burdens were determined by 
quantifying the GFP signal using ImageJ software and are represented as corrected total fluorescence. n=4–5 mice per group. 
There are no data points for untreated cohorts on day 25 as the tumor burdens were too high to determine accurately. Data 
shown as mean±SEM. **P≤0.01. Act +Exo, activated with exosomes only; Act +Exo+ExoBlock, activated with exosomes and 
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We next tested the immunosuppressive ability of 
these exosomes by determining their effect on T- cell 
activation, measured by the CD69 upregulation assay 
described earlier. As predicted, melanoma- derived 
exosomes significantly inhibited (by 36%) the upregula-
tion of CD69 (figure 4B,C). Treatment with ExoBlock was 
found to reduce this inhibition to 10%, representing a 
71% reversal. We also observed a near- complete reversal 
of IL- 2 expression with ExoBlock (online supplemental 
figure S4C). We conclude that exosomes present in the 
DM6- Mut melanoma TME are immunosuppressive, and 
that treatment with ExoBlock can reverse this exosome- 
associated immunosuppression.
Having demonstrated the presence of PS+ exosomes in 
two different TMEs, their ability to suppress T- cell func-
tion, and the ability of ExoBlock to reverse this suppres-
sion in vitro, we predicted that by targeting PS with 
ExoBlock, it would be possible to enhance the T cell- 
dependent antitumor response in vivo. The design and 
validation of two tumor xenograft models, the X- mouse 
model,18 and the OTX model19 for evaluating the thera-
peutic efficacy of ExoBlock in vivo made it possible for us 
to test our prediction.
In vivo efficacy of ExoBlock demonstrated using the X-mouse 
model
The in vivo therapeutic efficacy of ExoBlock was first 
tested in the X- mouse model, a preclinical model 
designed and validated specifically for the purpose of 
evaluating immunotherapeutic strategies designed to 
enhance antitumor T- cell responses.18 This model uses 
Green Fluorescent Protein (GFP)+ DM6- Mut cells that 
express patient- derived tumor neoantigens in the context 
of HLA- A*02:01, making them tumor targets. Xenografts 
are established in the greater omentum of NSG mice 
by the intraperitoneal injection of 2.5×106 tumor target 
cells. As stated previously, these tumors progress rapidly 
and metastasize if left untreated. The adoptive transfer of 
5×105 patient- derived T cells (TKT R438W cells) specific 
for the peptides expressed on these tumor targets into 
5- day- old xenografts results in an immediate suppression 
of tumor growth. This initial suppression is followed by 
tumor escape. The X- mouse model allows us to evaluate 
the efficacy of immune- based therapies that enhance 
T- cell function by determining their ability to prevent 
or suppress this tumor escape. This model has been vali-
dated by demonstrating the efficacy of two such immune- 
based therapies—IL- 12 and anti- PD- 1 (nivolumab) in 
suppressing tumor escape.18
Having established that DM6- Mut tumors release PS+ 
immunosuppressive exosomes and that ExoBlock reverses 
the exosome- mediated T- cell immune suppression, we 
next used the X- mouse model to test the therapeutic effi-
cacy of ExoBlock in vivo and compared it with checkpoint 
blockade using the anti- PD- 1 antibody nivolumab—a 
Food and Drug Administration- approved treatment for 
metastatic melanoma.26 Xenografts were established 
with DM6- Mut melanoma cells, and tumor- specific T 
cells (TKT R438W) and ExoBlock or nivolumab was 
administered by intraperitoneal injection on the indi-
cated days (figure 4D). The dose of ExoBlock was deter-
mined based on pharmacokinetic considerations, and the 
concentrations were used to block the exosome- mediated 
T- cell suppression in vitro. On day 25, mice were eutha-
nized, and the omental tumor burdens were measured 
by quantifying the GFP signal as described previously.18 
We found that ExoBlock significantly reduced tumor 
growth (twofold reduction of GFP intensity on day 25), 
and tumor suppression was comparable to checkpoint 
blockade using nivolumab (figure 4E,F). The untreated 
mice developed ascites fluid and extensive metastasis by 
day 25, necessitating euthanasia, while the ExoBlock- 
treated mice did not show any of these signs, presumably 
conferring a survival advantage. We also demonstrate that 
the efficacy of ExoBlock is dependent on T cells, since 
ExoBlock had no effect on the growth of DM6- Mut tumors 
in the absence of TKT R438W cells (online supplemental 
figure S5). These studies establish the efficacy of ExoB-
lock in vivo in human melanoma tumors.
In vivo efficacy of ExoBlock demonstrated using the OTX 
model
Since adoptively transferred T cells are the only immune 
cells present in the microenvironment of the X- mouse 
model,18 we also tested ExoBlock in a more complete 
TME. This was done using the previously established 
OTX model,19 which comprises intraperitoneal injec-
tion of small aggregates of tumors derived from patients 
with ovarian cancer into NSG mice, resulting in a rapid 
and preferential engraftment of a TME including tumor- 
associated stromal fibroblasts, macrophages, B and T 
lymphocytes, and tumor cells in the greater omentum of 
these mice.19 Analysis of tumor burden and T- cell tran-
scripts was performed by real- time quantitiative reverse 
transcription polymerase chain reaction (qRT- PCR) of 
the greater omentum following treatment with three 
intraperitoneal injections of ExoBlock (figure 5A). ExoB-
lock was not only found to reduce the tumor burden by 
92% (figure 5B) but also resulted in a 7.6- fold increase 
in numbers of CD8 T cells (figure 5C), 4.0- fold increase 
in CD4 T cells (figure 5D), and 3.3- fold increase in IFN-γ 
(figure 5E)—a measure of activated T- cell responses in 
the tumor xenograft, establishing its immune- enhancing 
effect. As a result, the tumor (EpCAM):CD8 T- cell ratio, 
which represents the dynamic between tumor growth 
and immune responses, is reversed on ExoBlock treat-
ment (figure 5F). ExoBlock also affected macrophage 
polarization by increasing the proportion of the immune- 
stimulatory M1 macrophages, thus increasing the M1:M2 
ratio in the TME (figure 5G, (online supplemental figure 
S6). Additionally, the incidence of metastasis was found 
to be significantly reduced in the ExoBlock- treated 
group (figure 5H), suggesting a possible survival advan-
tage. To determine the effect of ExoBlock treatment 
on the number of circulating PS+ exosomes, we quan-
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day 25 xenografts using imaging IFC. Sera derived from 
ExoBlock- treated xenografts displayed a 60% reduction 
in the number of PS+exosomes compared with sera from 
the control cohorts (figure 5I and online supplemental 
figure S7). ExoBlock was tested in multiple xenografts 
established using ovarian tumors from five different 
patients and was found to be reproducibly efficacious in 
reducing tumor burden as well as in enhancing immune 
responses (figure 5J). The effect of ExoBlock treatment 
on regulatory T cells, quantified using Foxp3, was found 
to be variable (figure 5J).
Flow cytometric analysis of untreated and ExoBlock- 
treated OTX xenografts (figure 6A) demonstrated a 
significant increase in the proportions as well as in cell 
numbers (per xenograft) for total T cells (figure 6B–D), 
CD4 T cells (figure 6E–G), and CD8 T cells (figure 6H–J), 
corroborating the results from gene expression analysis 
using qRT- PCR.
We propose that ExoBlock binds to PS on exosomes, 
thereby blocking immunosuppression (figure 7). This 
results in a reactivation or rescue of T cells that are tran-
siently suppressed by the exosomes in TMEs, which in 
Figure 5 ExoBlock suppresses tumor growth and enhances immune responses in the OTX model. (A) Experimental scheme 
indicating the timeline for injection of tumor cells (green arrow), ExoBlock (blue arrows), and experimental endpoint (red arrow). 
On day 25, the animals were euthanized; omenta were harvested; and the expression of different genes were analyzed using 
qRT- PCR. Relative expression level of EpCAM (for tumor burden) (B), CD8 (C), CD4 (D), and IFN-γ (E) are shown. (F) EpCAM 
to CD8 ratio and (G) M1:M2 macrophage ratio are shown. (H) Incidence of metastasis and (I) the number of circulating PS+ 
exosomes per millilitre of serum are shown. Whiskers and outliers were calculated using the Tukey method. n=6 for (G) and n=8 
for all the others. Mean fold change in tumor burden, T cells and metastasis in ExoBlock- treated mice normalized to control 
mice (set as 1) is shown in (J). Xenografts of 5–10 were established for each patient tumor. Data shown as mean±SEM. *P≤0.05, 
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turn suppress tumor growth (figure 7). A reduced tumor 
burden results in a decrease in PS+ exosomes being 
produced over time, gradually reversing the immuno-
suppressive nature of the TME. Together, our results 
establish the therapeutic potential of ExoBlock as a 
PS- blocking molecule while also confirming the viability 
of approaches targeting immunosuppressive exosomes in 
TMEs.
DISCUSSION
The exposure of PS on the surface of apoptotic cells 
was initially thought of as playing the role of a ‘cleanup 
crew’, sending an ‘eat- me’ signal to macrophages for 
the purpose of clearance.23 27 Subsequent studies have 
established that PS facilitates an immunologically silent 
clearance and plays an active immunosuppressive 
role by inducing tolerance to antigens associated with 
it.23 28 29 The immunosuppressive role of PS has also been 
demonstrated in exosomes isolated from TMEs, where 
they have been shown to arrest T- cell activation through 
the TCR.6 This immune suppression was found to be caus-
ally linked to PS on the exosomal surface.6 This makes 
PS an attractive target to neutralize in order to enhance 
immune responses in cancer, and possibly also in chronic 
inflammatory conditions, where a similar role for PS+ 
exosomes has been described.30 Initial proof- of- concept 
studies showed that anti- PS antibody could reverse tumor 
exosome- mediated immunosuppression significantly.6 
Strategies to block PS in preclinical studies using anti- PS 
antibodies and annexin V or to treat lung cancer in clin-
ical trials using a PS specific antibody, bavituximab,23 have 
met with modest success, perhaps due to the relatively 
low PS- binding affinity of the molecules used and the 
relatively high molecular weight of the antibody. ExoB-
lock is a hexamer that has been engineered to carry six 
binding sites for PS, which is more than an antibody or 
Figure 6 ExoBlock enhances T- cell numbers in the OTX model. (A) Experimental scheme indicating the timeline for injection 
of tumor cells (green arrow), ExoBlock (blue arrows), and experimental endpoint (red arrow). On day 25, the animals were 
euthanized; omenta were harvested; and the percentages as well as total cell numbers of different T- cell subsets in the 
xenografts were quantified using flow cytometry and cell counts. (B, E,H) Representative data, (C,F,I) compiled percentages; and 
(D,G,J) cell numbers per xenograft are shown for total T cells (CD3+), CD4 T cells (CD3 +CD4+), and CD8 T cells (CD3 +CD8+), 
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annexin V and hence expected to bind PS with a much 
higher avidity. We have determined that ExoBlock does 
indeed bind PS with a high avidity and is very effective 
in blocking immune suppression of multiple T- cell activa-
tion endpoints mediated by exosomes derived from two 
different TMEs in vitro. The fact that ExoBlock was able 
to reverse 70% of exosome- mediated immune suppres-
sion in vitro for multiple activation endpoints indicates 
that PS expression is critical for exosome- mediated 
immune suppression. It is however not surprizing that the 
reversal was not total in these experiments, since various 
other molecules, including proteins such as PD- L116 and 
TGF-β,31 lipids such as ganglioside GD3,8 and nucleic 
acids such as miR- 24–3 p32 have been also known to be 
causally linked to the immunosuppressive nature of these 
vesicles.
To test the in vivo therapeutic efficacy of ExoBlock 
on human tumors, we then used two different in- house 
developed tumor xenograft models. The first, the 
melanoma- based X- mouse model, was designed and 
validated for the purpose of preclinically evaluating the 
efficacy of immune- based therapies that enhance the 
antitumor responses of patient- derived tumor- specific T 
cells.18 The X- mouse model has multiple advantages, such 
as providing a controlled system in which the number of 
tumor cells used to establish tumor xenografts is known; 
the timing and number of T cells that are adoptively 
transferred into tumor‐bearing mice is controlled; and 
the tumor specificity of the T cells for tumor antigens is 
well defined.18 Since adoptively transferred T cells are the 
only immunocompetent cells present in the TME in this 
model, the suppression of tumor growth can be directly 
interpreted as being a result of enhanced antitumor T- cell 
responses.
Since the X- mouse model lacks other immune cells and 
stroma, which impact therapeutic efficacy, we also tested 
ExoBlock in a more complete TME represented by the 
ovarian tumor- based OTX model.19 In all the patient 
tumors tested, ExoBlock was found to significantly 
suppress tumor growth and metastasis, with a concomi-
tant increase in CD4 and CD8 T cells, as well as in IFN-γ 
expression, an indicator of T- cell responses. While there 
was some variability in the degree of tumor suppression 
and enhancement of immune responses in different 
tumors as expected, these data trended in the same 
direction for all the tumors tested. Since the only T cells 
in these tumors are the tumor- infiltrating lymphocytes 
(TILs) present in the original tumor aggregates injected 
on day 0, these data indicate that the dysfunction of at 
least a subset of TILs is reversible. This is consistent with 
previous studies from our lab, given our findings that lipo-
somally delivered IL- 12 reactivates hyporesponsive T cells 
in the TME,33–36 and bodes well for immune- based ther-
apies that are designed to enhance T- cell function. The 
direct effect of ExoBlock on CD4 and CD8 T cells in the 
OTX model, along with results from the X- mouse model 
that demonstrate the requirement for T cells, establishes 
that the efficacy of ExoBlock is dependent on restoring 
T- cell function, therefore representing an immune- based 
therapy.
An enhancement of immune responses is expected to 
ultimately result in the generation of Tregs, or upregu-
lation of checkpoint molecules such as PD- 1 as a natural 
regulatory mechanism. This raises the possibility of 
Figure 7 Schematic representation of the neutralization of immunosuppressive PS+ exosomes by ExoBlock. (A) In tumor 
microenvironments, PS+ exosomes suppress T- cell activation, proliferation and cytotoxic activity leading to tumor growth. (B) 
Treatment with ExoBlock neutralizes immunosuppressive exosomes, resulting in a restoration of T- cell function and ultimately 
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combining ExoBlock with IL- 12, which activates T cells 
while also suppressing checkpoint upregulation,18 and/
or checkpoint blockade therapy such as nivolumab to 
improve the therapeutic efficacy. Future studies will test 
the efficacies of these combinations in our xenograft 
models. The effect of ExoBlock on additional immune 
cell subsets that influence tumor growth such as Th17 
cells and myeloid- derived suppressor cells will also be 
investigated. While there are indications that ExoBlock 
treatment confers a survival benefit to tumor- bearing 
mice, we recognize that this needs to be thoroughly 
tested in one or more tumor models. We plan to extend 
these studies by investigating the effect of ExoBlock on 
TME using immunocompetent syngeneic mouse tumor 
models. These models will also allow us to generate longi-
tudinal tumor growth data, the lack of which is one of the 
limitations of the current study.
We recognize that PS is present not just on exosomes 
but also on apoptotic cells and cancer cells as a mecha-
nism of immune evasion. ExoBlock is expected to bind to 
all PS, therefore representing a multipronged approach 
to negate PS- induced immunosuppression. Additionally, 
ExoBlock may also negate other effects PS might be medi-
ating in TMEs. We also recognize that translating this 
blockade of immunosuppression to clinically efficacious 
targeting of exosomes in the TME to enhance immune 
responses will remain a challenge until the biology of 
exosomes and their role in immune and non- immune 
cellular interactions is better understood.
To conclude, our results show that targeting immu-
nosuppressive exosomes using a high- avidity PS- binding 
molecule such as ExoBlock may represent a prom-
ising strategy to combat immunosuppression and T- cell 
dysfunction in human TMEs, providing a rationale for 
further development and characterization of ExoBlock.
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Figure S1: Synthetic scheme to produce (ZnDPA)6-DP-15K i.e. ExoBlock. DPA-amine (1) is prepared from 
3,5-dicarboxymethylphenol in 5 synthetic steps according to a literature procedure (Lakshmi, C, Hanshaw 
RG, Smith BD. 2004. Fluorphore-linked zinc(II) dipicolylamine coordination complexes as sensors for 
phosphatidylserine-containing membranes. Tetrahedron, 60, 11307-11315). Reaction of (1) (523mgs, 
0.890mmol) with glutaric anhydride (107mgs, 0.940 mmol) in chloroform (20 mL) for 24h at room 
temperature and concentration of the mixture provides compound (2) in quantitative yield. Treatment of 
(2) (593mgs, 0.850mmol) with the water soluble coupling agent, 1-ethyl-3(3-
dimethylaminopropyl)carbodiimide (189mgs, 0.984mmol) and N-hydroxysulfosuccinimide (234mgs, 
1.078mmol) in anhydrous DMF (12mL) for 20h at room temperature gives the activated ester 
intermediate in situ.  Next, 6-arm-PEG-amine (dipentaerythritol), HCl salt, MW=15,000 (450mgs, 29.7 
moles, Jenkem Technology) in DMF (10mL) containing 50uL of N,N-diisopropylethylamine is added and 
the mixture stirred at room temperature overnight to provide (3).  The DMF is then removed by rotary 
evaporation and zinc nitrate hexahydrate (630mg, 2.12 mmol) in 40mL of methanol is added and the 
mixture stirred for 24h.  The methanol is then removed by rotary evaporation and the residue taken up in 
water (30mL) and transferred to three 10mL dialyzer tubes of  MWCO=8-10kDa (Spectra-Por Float-A-
Lyzer).  Bags are placed in 3L of water and stirred with 3 water changes at 2h, 6h and 24h.  Solutions from 
dialysis bags are combined and filtered through a 0.2um PTFE Nalgene filter and the solution is freeze 
dried overnight to provide 560mgs of ExoBlock as a white solid.  
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Figure S7: ExoBlock decreases circulating PS+ exosomes in the OTX model. Representative images for 
the imaging flow cytometric (IFC) determination of PS+ exosomes from day 25 omental tumor xenografts. 
Exosomes were identified using ExoGlow and PS expression was determined using PSVue binding. 
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SUPPLEMENTARY METHODS 
Isolation of tumor-associated exosomes: Ascites fluids (from ovarian tumor patients, or mice 
bearing DM6-Mut tumors), or medium in which DM6-Mut tumors were mechanically disrupted 
were first centrifuged at 300 x g to remove cells and large debris, followed by another round of 
centrifugation at 1,150 x g to remove smaller debris and membrane fragments. They were then 
diluted to 50% (with RPMI-1640 or PBS), passed through a 0.22 µm PVDF filter (Millipore), and 
ultracentrifuged at 200,000 x g for 90 minutes. The pellet was resuspended in RPMI-1640 + 1% 
HSA (for functional experiments) or PBS (for biophysical characterization).  
Exosome antibody array: The identification of protein markers on isolated exosomes was done 
using a commercially available Exo-Check exosome antibody array (System Biosciences Inc.) kit 
as described by the manufacturer. The membrane was developed with SuperSignal West Femto 
Maximum Sensitivity Substrate (Thermo Fisher Scientific) and analyzed using ChemiDoc MP 
System (BioRad). 
Nanotracking analysis (NTA): Particles were diluted in a final volume of 1 mL in sterile 1x PBS 
for NTA measurements. All NTA measurements were conducted with a ZetaView particle tracking 
analyzer equipped with a 488 nm laser (ParticleMetrix, Mebane, NC). Instrument performance 
was checked daily using 100 nm beads using the ZetaView acquisition software (version 8.05.04) 
quality control suite. The camera settings for the basic acquisition protocol for data acquisition 
included a sensitivity of 82, shutter speed of 150, and a frame rate of 30 with applied post-
acquisition parameters of minimum brightness 20, minimum size 10, maximum size 200 and trace 
length 15. Eleven positions were recorded for each sample with 2 cycles at each position.  Camera 
sensitivity settings were checked and adjusted where necessary for each sample but generally this 
would result in less than 2-3 percentage points from the saved protocols. For determining size 
distribution, the data (as fcs files) were analyzed using FlowJo. 
Flow Exometry: Three hundred to five hundred micrograms of exosomes were attached to 100 μl 
of aldehyde/sulfate latex beads (4 μm; 4% w/v) and incubated overnight at 4°C on a rotator/ mixer. 
Glycine was then added to a final concentration of 100 mM to saturate remaining free binding sites 
on the beads. The beads were then washed in PBS with 0.5% BSA and used for 
immunofluorescence staining with an unconjugated anti-PS antibody (Clone 1H6, Upstate) and a 
secondary antibody goat anti-mouse IgG AlexaFluor 488 (Life Technologies). 
T cell activation with antibodies to CD3 and CD28: Antibodies were immobilized on maxisorp 12 
× 75 mm tubes (Nunc) by incubating 0.1 μg of purified anti-CD3 (Bio X Cell, catalog number 
BE001-2; clone OKT3) and 5 μg of purified anti-CD28 (Life Technologies, catalog number 
CD2800-4; clone 10F3) in 500 μl of PBS, at 4°C overnight. PBL from normal donors was thawed, 
resuspended in RPMI-1640 + 1% human serum albumin, and 5 x 105 total cells were incubated in 
anti-CD3/anti-CD28 in coated tubes at 37°C/5% CO2 for the duration of activation. 
Detection of NFκB translocation following T cell activation: Human NDPBL were activated for 
2h at 37°C with immobilized anti-human CD3/CD28 with or without ovarian ascites fluid-derived 
exosomes. The percentage of activated T cells was determined by monitoring the translocation of 
NFκB from the cytosol into the nucleus using fluorescence microscopy as previously reported (7).  
Detection of CD69 expression following T cell activation: Human NDPBL were activated for 2h 
at 37°C with immobilized anti-human CD3/CD28 with or without exosomes (derived from either 
ovarian ascites fluid or DM6-Mut xenograft ascites fluid). The cells were then incubated for 18h 
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in RPMI-1640 + 1% HSA at 37oC/5% CO2 in the absence of stimulation or exosomes. For flow 
cytometry, cells were labeled with the recommended amounts of fluorochrome-conjugated 
antibodies to CD3 (clone UCHT1, BD Biosciences) and CD69 (clone L78, BD Biosciences) for 
30 mins at 4oC.  The cells were then washed with 2 mL of PBS and labeled with Sytox Red (Life 
Technologies) for 15 min, acquired on an LSR Fortessa (BD Biosciences) flow cytometer and 
analyzed using FlowJo software. 
Detection of CD25 expression following T cell activation: Human NDPBL were activated for 72h 
at 37°C with immobilized anti-human CD3/CD28 with or without exosomes and ExoBlock. For 
flow cytometry, cells were labeled with the recommended amounts of fluorochrome-conjugated 
antibodies to CD3 (clone UCHT1, BD Biosciences) and CD25 (clone M-A251, BD Biosciences) 
for 30 mins at 4oC.  The cells were then washed with 2 mL of PBS and labeled with Sytox Red 
(Life Technologies) for 15 min, acquired on an LSR Fortessa (BD Biosciences) flow cytometer 
and analyzed using FlowJo software. 
Detection of intracellular IL-2 expression following T cell activation: Human NDPBL were 
activated for 6h at 37oC/5% CO2 with immobilized anti-human CD3/CD28 in the presence of 1 
L/mL GolgiStop (BD Biosciences) with or without DM6-Mut ascites derived exosomes and 
ExoBlock. For flow cytometry, cells were labeled with fluorochrome-conjugated antibodies to 
CD3 (clone UCHT1, BD Biosciences) for 30 mins at 4oC. The cells were then fixed and 
permeabilized with the fixation/permeabilization solution from the Cytofix/Cytoperm kit (BD 
Biosciences) as described by the manufacturer and labeled with fluorochrome-conjugated 
antibodies to IL-2 (clone 5344.111, BD Biosciences) at 4oC for 30 min, washed, fluorescence 
emission acquired, and results analyzed as above. 
Detection of intracellular IFN-γ expression following T cell activation: Human NDPBL were 
activated for 72h at 37oC/5% CO2 with immobilized anti-human CD3/CD28 with or without 
exosomes and ExoBlock. 1 L/mL GolgiStop (BD Biosciences) was added and cells were cultured 
for 5 more hours. For flow cytometry, cells were labeled with fluorochrome-conjugated antibodies 
to CD3 (clone UCHT1, Tonbo Biosciences) for 30 min at 4oC. The cells were then fixed and 
permeabilized with the fixation/permeabilization solution from the Cytofix/Cytoperm kit (BD 
Biosciences) as described by the manufacturer and labeled with fluorochrome-conjugated 
antibodies to IFN-γ (clone B27, BD Biosciences) at 4oC for 30 min, washed, fluorescence emission 
acquired, and results analyzed as above. 
Proliferation assay: Human NDPBL were labeled with CellTrace Violet Proliferation kit (Thermo 
Fisher Scientific) as recommended by the manufacturer. The labeled cells were incubated in tubes 
that were coated with immobilized antibodies to human CD3 and CD28 for 7 days with or without 
ascites fluid-derived exosomes and ExoBlock. On day 7, the cells were labeled with fluorochrome-
conjugated anti-human CD3 (clone UCHT1, Tonbo Biosciences). Sytox Red was added 15 min 
before flow cytometry at a final concentration of 5 nM to label the dead cells. The fluorescence 
was acquired on an LSR Fortessa (BD Biosciences) flow cytometer. The data were analyzed using 
FlowJo software (Tree Star Inc.) to calculate the expansion index. 
Calculation of % inhibition and % reversal: These were calculated using the formulae: 
% Inhibition = [1- (% activation with exosomes / % activation without exosomes)] × 100 
% Reversal = [1- (% inhibition in test group / % inhibition in control group)] × 100 
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Establishment of the X-mouse Model: NSG mice were implanted with 2.5 x 106 DM6-Mut cells 
intraperitoneally (i.p.) in a total volume of 0.5 mL. Cryopreserved neoantigen-specific TKT cells 
were thawed and incubated in complete medium for 6h at 37°C and 5% CO2. 5 x 10
5 T cells were 
injected i.p. per mouse in a total volume of 0.5 mL, 5 days following the implantation of DM6-
Mut cells.  
Analysis of tumor burden in the X-mouse model: 25 days following implantation of the tumor, the 
mice were euthanized and the greater omentum from each mouse was surgically removed. A wet 
mount of the omentum in PBS was scanned using the Leica DM6 B upright fluorescence 
microscope. The entire omentum was scanned under the 5X objective using the GFP and DIC 
filters. Measurements were made in a random order for control and test groups to minimize 
confounders .The images were exported as TIF files and analyzed using ImageJ software to 
quantify the GFP signal. The polygon tool was used to draw a tight border around the omentum 
and the amount of signal was measured in the green channel. Background in the green channel was 
also measured by drawing a gate in a region of the omentum that was free of any tumor cells. 
Corrected total fluorescence was then calculated using the formula CTF = Intensity Density of 
Omentum- (Area of Omentum x Mean Gray Value of Background for that omentum).  
Establishment of the OTX Model: NSG mice were implanted with 150 mg of ovarian tumor 
aggregates (obtained by mechanical disruption of the patient tumor) intraperitoneally (i.p.) in a 
total volume of 0.5 mL.  
Recovery and analysis of T cells from OTX xenografts: T cells were recovered from the omenta of 
xenograft-bearing mice by the previously described walkout method18. Omenta were harvested 
under sterile conditions and placed in complete medium in wells of a 6-well tissue culture plate. 
The omenta were gently cut into small 4-5 mm pieces and incubated overnight at 37°C under 5% 
CO2. On the following day, the medium with the “walkout cells” was passed through a 70 µm cell 
strainer to exclude omental tissue and debris. For flow cytometry, the cells were labeled with CD3 
(clone UCHT1, Tonbo Biosciences), CD4 (clone RPA-T4, BD Biosciences) and CD8 (clone RPA-
78, BD Biosciences). Dead cells were excluded using Ghost Dye Red 710 (Tonbo Biosciences). 
When blinding was not possible due to the nature of the experiment, we have minimized bias by 
randomization of animals assigned to control and test cohorts, using objective and reliable 
outcomes, duplicate assessment, and minimizing potential confounders. 
Imaging Flow Cytometry (IFC): IFC analysis was performed on an ImageStreamX MK-II platform 
(ISX, Amnis®, Luminex Corp, Seattle, WA). An acquisition live gate was set based on the scatter 
signal (detected in Ch12) to include events with scatter from zero through to approximately 1-5 % 
of the Speedbead scatter signal. Speedbeads, which are an integral part of the platform, are 1-
micron polystyrene beads that are intermixed with a sample during acquisition and are required to 
synchronize the sample velocity and time-delayed integration of the charge coupled device (CCD) 
camera in the system. All samples were acquired for a set time of 20 seconds.  Single color controls 
were run (with the brightfield and scatter detectors off) to create a compensation matrix to correct 
the raw data for spectral overlap between the two dyes in the detection channels used. The 785nm 
laser (10mW) was used as the scatter and the 488nm laser (200 mW) was used to excite PsVue 
and Exoglow. For analyses in the IDEAS® software (version 6.2; Amnis, Luminex Corp) gates 
were applied to exclude any Speedbead events. Since the Imagestream platform is volumetric, the 
“objects/mL” parameter is a default statistic available for every experimental run. PsVue was 
detected in Ch2 and ExoGlow in Ch4. The particle concentrations were determined by the 
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objects/mL statistic and corrected for any pre-acquisition dilutions necessary to obtain an event 
rate that was within the camera processing speed capability of approximately 15,000 
events/second. Final exosome concentrations reflect corrections for applied dilutions before 
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Supplementary Table 1: List of primers used in qRT-PCR 
 




CD8 Forward CAGTCTTCCTCCCTGTGTATTC 
Reverse CCCTTGTGGTGTACTGTAGATT 
EpCAM Forward CCAGAACAATGATGGGCTTTATG 
Reverse CTCGCTCAGAGCAGGTTATTT 
IFN-γ Forward GGTCATTCAGATGTAGCGGATAA 
Reverse CTTGATGGTCTCCACACTCTTT 
Foxp3 Forward TTCCTCCACAACATGGACTAC 
Reverse TGGTTTCTGAAGAAGGCAAAC 
Beta-Actin Forward TAGTTGCGTTACACCCTTTCTT 
Reverse CGGCCACATTGTGAACTTT 
CD86 Forward CTGTAACTCCAGCTCTGCTCCGTA 
Reverse GCCCATAAGTGTGCTCTGAAGTGA 
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